Hoover's - A D&B Company - We Make It Easier
Buy Reports For This Company

GALENA BIOPHARMA, INC.
PortlandOR United States
  (NASDAQ: GALE)

btn-overview-2btn-people-1btn-competition-1

Company Description

While there's no vaccine for breast cancer, Galena Biopharma has big plans for NeuVax, its drug candidate. NeuVax, which is in Phase III clinical trials, is being tested for its efficacy in reducing the recurrence of breast cancer in patients who can't take Genentech's Herceptin. Galena Biopharma acquired the rights to NeuVax when it bought the drug's developer, Arizona-based Apthera, Inc., for about $7 million in April 2011. Galena itself was spun off from RXi Pharmaceuticals in a one-for-one stock split in March 2012. Galena, having more potential for success with NeuVax, became the public company while RXi Pharmaceuticals became a private company focused on developing RNA interference (RNAi) therapies.

4640 Sw Macadam Ave Ste 270Phone: +1-855-855-4253http://www.galenabiopharma.com
PortlandOR 97239Fax: -Map Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

btn-free-trial

Prepare for your Sales call

Try a Small Business Subscription
Starting $89 per month

btn-subscribe-now

GALENA BIOPHARMA, INC. Rankings

Russell 2000 (June 2014)

Executives

22 executives listed for GALENA BIOPHARMA, INC.'s Portland, OR location.
ChairmanSanford HillsbergE-mail
President and CEOMark SchwartzE-mail
EVP and Chief Medical OfficerBrian HamiltonE-mail

More GALENA BIOPHARMA, INC. Executives

Financials

Company TypePublic - NASDAQ: GALE Headquarters
Fiscal Year-EndDecember
Employees60
D&B logoDNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on GALENA BIOPHARMA, INC. now.

  • Reduce risk.
  • Drive greater profitability.
  • Increase cash flow.
Get a Credit Report Now

Sponsored Links